Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Kartos Therapeutics, Inc.
Scientific Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia